deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03065192

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa

Sponsor: Neurocrine Biosciences

Conditions Basal Ganglia Disease Brain Diseases Central Nervous System Diseases Idiopathic Parkinson's Disease Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson's Disease Parkinsonian Disorders
Interventions VY-AADC01
Updated 14 times since 2017 Last updated: Mar 17, 2022 Started: May 11, 2017 Primary completion: Aug 10, 2021 Completion: Aug 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03065192, this PHASE1 trial focuses on Basal Ganglia Disease and Brain Diseases and remains completed. Sponsored by Neurocrine Biosciences, it has been updated 14 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Mar 2018 · 9 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Apr 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

▶ Show 9 earlier versions

  1. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Apr 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  6. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Jun 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Neurocrine Biosciences
  • Voyager Therapeutics
Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations